Go Pro
→ NASA's ISS Replacement Could Go to This Tiny Space Firm (From Behind the Markets) (Ad)tc pixel Free KLDO Stock Alerts

Kaleido Biosciences (KLDO) Competitors

Kaleido Biosciences logo
$0.0001 0.00 (0.00%)
As of 10:37 AM Eastern
Compare

KLDO vs. MVLA, PRST, KBNT, AISPW, and APCXW

Should you buy Kaleido Biosciences stock or one of its competitors? Kaleido Biosciences's main competitors and comparable companies include Movella (MVLA), Presto Automation (PRST), Kubient (KBNT), Airship AI (AISPW), and AppTech Payments (APCXW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Kaleido Biosciences compare to Movella?

Movella (NASDAQ:MVLA) and Kaleido Biosciences (NASDAQ:KLDO) are both small-cap technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

40.9% of Movella shares are held by institutional investors. Comparatively, 81.6% of Kaleido Biosciences shares are held by institutional investors. 20.0% of Movella shares are held by insiders. Comparatively, 9.0% of Kaleido Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Movella's average media sentiment score of 0.00 equaled Kaleido Biosciences'average media sentiment score.

Company Overall Sentiment
Movella Neutral
Kaleido Biosciences Neutral

Movella has higher earnings, but lower revenue than Kaleido Biosciences. Movella is trading at a lower price-to-earnings ratio than Kaleido Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Movella-$559K-0.04-$220K-$0.62N/A
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A

Company Net Margins Return on Equity Return on Assets
MovellaN/A N/A N/A
Kaleido Biosciences N/A N/A N/A

Movella has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, Kaleido Biosciences has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market.

Summary

Movella and Kaleido Biosciences tied by winning 4 of the 8 factors compared between the two stocks.

How does Kaleido Biosciences compare to Presto Automation?

Kaleido Biosciences (NASDAQ:KLDO) and Presto Automation (NASDAQ:PRST) are both small-cap technology companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

Kaleido Biosciences has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market. Comparatively, Presto Automation has a beta of -3.45, suggesting that its share price is 445% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Kaleido BiosciencesN/A N/A N/A
Presto Automation N/A N/A N/A

Presto Automation has higher revenue and earnings than Kaleido Biosciences. Kaleido Biosciences is trading at a lower price-to-earnings ratio than Presto Automation, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A
Presto Automation$19.05M0.00-$34.48M-$1.23N/A

In the previous week, Kaleido Biosciences' average media sentiment score of 0.00 equaled Presto Automation'saverage media sentiment score.

Company Overall Sentiment
Kaleido Biosciences Neutral
Presto Automation Neutral

81.6% of Kaleido Biosciences shares are held by institutional investors. Comparatively, 20.9% of Presto Automation shares are held by institutional investors. 9.0% of Kaleido Biosciences shares are held by company insiders. Comparatively, 10.0% of Presto Automation shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Presto Automation beats Kaleido Biosciences on 4 of the 7 factors compared between the two stocks.

How does Kaleido Biosciences compare to Kubient?

Kubient (NASDAQ:KBNT) and Kaleido Biosciences (NASDAQ:KLDO) are both small-cap technology companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

13.9% of Kubient shares are owned by institutional investors. Comparatively, 81.6% of Kaleido Biosciences shares are owned by institutional investors. 22.3% of Kubient shares are owned by insiders. Comparatively, 9.0% of Kaleido Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Kubient has higher revenue and earnings than Kaleido Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kubient$1.17M0.00-$13.62MN/AN/A
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A

Company Net Margins Return on Equity Return on Assets
KubientN/A N/A N/A
Kaleido Biosciences N/A N/A N/A

Kubient has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, Kaleido Biosciences has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market.

In the previous week, Kubient's average media sentiment score of 0.00 equaled Kaleido Biosciences'average media sentiment score.

Company Overall Sentiment
Kubient Neutral
Kaleido Biosciences Neutral

Summary

Kubient beats Kaleido Biosciences on 4 of the 7 factors compared between the two stocks.

How does Kaleido Biosciences compare to Airship AI?

Airship AI (NASDAQ:AISPW) and Kaleido Biosciences (NASDAQ:KLDO) are both technology companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

81.6% of Kaleido Biosciences shares are owned by institutional investors. 9.0% of Kaleido Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Airship AIN/A N/A N/A
Kaleido Biosciences N/A N/A N/A

Airship AI has higher revenue and earnings than Kaleido Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Airship AI$18.15MN/AN/AN/AN/A
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A

In the previous week, Airship AI had 1 more articles in the media than Kaleido Biosciences. MarketBeat recorded 1 mentions for Airship AI and 0 mentions for Kaleido Biosciences. Airship AI's average media sentiment score of 0.00 equaled Kaleido Biosciences'average media sentiment score.

Company Overall Sentiment
Airship AI Neutral
Kaleido Biosciences Neutral

Summary

Airship AI and Kaleido Biosciences tied by winning 2 of the 4 factors compared between the two stocks.

How does Kaleido Biosciences compare to AppTech Payments?

Kaleido Biosciences (NASDAQ:KLDO) and AppTech Payments (NASDAQ:APCXW) are both technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

In the previous week, Kaleido Biosciences' average media sentiment score of 0.00 equaled AppTech Payments'average media sentiment score.

Company Overall Sentiment
Kaleido Biosciences Neutral
AppTech Payments Neutral

AppTech Payments has lower revenue, but higher earnings than Kaleido Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A
AppTech Payments$276KN/AN/AN/AN/A

81.6% of Kaleido Biosciences shares are held by institutional investors. 9.0% of Kaleido Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Kaleido BiosciencesN/A N/A N/A
AppTech Payments N/A N/A N/A

Summary

Kaleido Biosciences beats AppTech Payments on 3 of the 3 factors compared between the two stocks.

Get Kaleido Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for KLDO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KLDO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KLDO vs. The Competition

Export
MetricKaleido BiosciencesSoftware IndustryTechnology SectorNASDAQ Exchange
Market Cap$4K$15.90B$30.86B$13.10B
Dividend YieldN/A3.41%2.75%12.57%
P/E Ratio0.00142.4779.1225.77
Price / Sales0.001,284.67586.6097.61
Price / CashN/A47.5449.7052.76
Price / BookN/A8.857.986.34
Net Income-$95.48M$434.54M$702.99M$360.00M
7 Day PerformanceN/A0.35%1.21%-0.11%
1 Month PerformanceN/A-2.59%-1.32%-3.42%
1 Year PerformanceN/A-1.27%178.25%5.46%

Kaleido Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KLDO
Kaleido Biosciences
N/A$0.00
flat		N/AN/A$4K$1.10MN/A76
MVLA
Movella
N/A$0.00
flat		N/A-90.0%$10K-$559KN/A3
PRST
Presto Automation
N/A$0.00
flat		N/AN/A$10K$19.05MN/A4
KBNT
Kubient
N/A$0.00
flat		N/AN/A$1K$1.17MN/A40
AISPW
Airship AI
N/A$0.39
+8.3%		N/A-80.0%$0.00$18.15MN/A47

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:KLDO) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
NASA's ISS Replacement Could Go to This Tiny Space Firm
NASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
AI Panic: Sell now or wait?
Bank of America, Goldman Sachs, and Morgan Stanley have reportedly warned private clients about a coming stock...
TradeSmith | Sponsoredtc pixel